Genetic Mutations and Ubiquitination in Melanoma Growth and Metastasis by Dikshit, Anushka & Zhang, Jennifer
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 8
Genetic Mutations and Ubiquitination in Melanoma
Growth and Metastasis
Anushka Dikshit and Jennifer Zhang
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.78733
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work is properly cited. 
Anushka Dikshit and Jennifer Zhang
Additional information is available at the end of the chapter
Abstract
Upon neoplastic transformation, melanoma is intrinsically prone to metastasis, which 
marks the most dangerous aspect of the disease and dubs it one of the most challenging 
cancers to treat. BRAF/MEK oncokinase inhibitors and immunotherapies have shown 
considerable promise in some patients, but the clinical benefits are often short-lived due 
to rapid development of resistance. Recently, ubiquitination enzymes have emerged as 
potential therapeutic targets. These enzymes can be targeted to increase expression of 
tumor suppressors and impede activation of oncogenic signaling pathways mediating 
cell proliferation and tissue invasion. This chapter describes some of the common genetic 
mutations in melanoma, ubiquitinating and deubiquitinating enzymes that are linked to 
melanoma progression, metastasis, and therapeutic resistance.
Keywords: A20, BAP1, BRAF, CDKN2A, CYLD, DUB, E-cadherin, ERK, melanoma, 
N-cadherin, Snail1, TRAF6, UBE2S, ubiquitination, USP
1. Introduction
Melanoma is the most aggressive form of skin cancer. The 5-year survival rate for metastatic 
melanoma is less than 20%. The incidence of melanoma is on the rise especially among the 
young population. The NIH SEER program estimated that 87,110 people were diagnosed with 
melanoma in the United States in 2017, accounting for 5.2% of all new cases of cancer, which 
is 1.2% higher than the melanoma cases reported in 2007. About 11% of the newly diagnosed 
patients would succumb to the disease due to uncontrollable metastatic tumor growth [1, 2]. 
This chapter describes the common genetic mutations and posttranslational modifications 
crucial for melanoma growth, survival and dissemination, with a particular focus on enzymes 
regulating ubiquitination.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Melanoma staging and diagnosis
Melanoma treatment plans are designed based on the stage of the disease. In 2017, the 
American Joint Committee on Cancer (AJCC) published the 8th edition of the tumor, lymph 
node, and metastasis (TNM) system. The T recognizes tumor thickness or the depth of the 
cancer in the skin and characterizes the tumor as being ulcerated or non-ulcerated. The N is 
used to establish whether the cancer has spread to the proximal lymph nodes and finally, the 
M stands for metastasis and gives information if the cancer has spread to distant lymph nodes 
or other organs [3]. Using the TNM numbers along with elaborate clinical and pathological 
assessments, the cancer is assigned a stage. Further histological analyses allow pathologists 
to assign a ‘grade’ to the tumor which is an indication of the abnormality of the tumor cells. 
Both staging and grading are crucial to determine the course of treatment and give an overall 
prognosis for the disease. Although it is under debate whether a linear progression is the 
primary theme, cutaneous melanomas can progress from a precursor lesion, namely benign 
nevi which becomes dysplastic, to melanoma in situ, and finally to invasive melanoma. A 
nevus is a benign aggregation of melanocytes that is formed at the junction of the dermis and 
epidermis or within the dermis. When the nevus shows signs of cytological atypia and change 
in growth, it becomes dysplastic. Melanoma in situ, also called as the stage (0) melanoma, is 
when the transformed melanocytes are still within the epidermis or the dermal/epidermal 
junction. Lastly, when the transformed melanocytes invade the dermis and gain access to 
other cell tissues and/or the vascular system, they turn into metastatic melanoma [4]. The 
development of melanoma involves multifactorial and heterogeneous biologic processes that 
are controlled at the genetic, transcriptional, and posttranslational levels [5, 6].
3. Genetic mutations
3.1. Germline mutations in melanoma
Certain genetic changes predispose an individual to an increased risk of melanoma. These 
changes include point mutations, amplifications, deletions or translocations. CDKN2A is one 
of the first genes linked to the familial atypical mole melanoma (FAMM). Deletion or loss 
of heterozygosity of CDKN2A increases patient susceptibility to developing melanoma [7]. 
Consistently, germline deletion of Cdkn2a in mice sensitizes animals to developing cutaneous 
melanoma when coupled with an activating HRAS mutation in the melanocytes [8]. While the 
CDKN2A gene codes for two proteins, p16 INK4A and p15 ARF, p16 INK4A loss-of-function 
is responsible for spontaneous and carcinogen induced melanoma [9]. CDK4 and RB1 are two 
other genes with germlines mutations linked to familial susceptibility to melanoma. CDK4, a 
kinase involved in regulating cell cycle, is amplified or mutated in human melanomas with 
some studies showing 100% of all the affected family members harboring a specific CDK4 
mutation [10, 11]. Inactivation of RB1 tumor suppressor causes hereditary retinoblastoma and 
increases the risk of developing melanoma by about 80-fold [12]. Variants of the melanocor-
tin-1 receptor (MC1R) are associated with fair pigmentation and melanoma risk [13]. The 
Cancer Metastasis126
presence of a CDKN2A mutation gave a hazard ratio of 13.35, and the MC1R variants increase 
the hazard ratio by 3.72-fold [14].
3.2. Somatic mutations in melanoma
Ultraviolet (UV) radiation induces somatic gene mutations and is the major risk factor for mela-
noma [6, 15]. The RAS/RAF/MEK/ERK signaling pathway is commonly mutated in melanoma. 
Among the RAS GTPase family members, NRAS is the most frequently mutated protein with 
activating mutations detected in up to 56% of benign nevi and 26% of metastatic melanoma [16, 
17]. Activating mutations of BRAF are found in about 70% of cutaneous melanomas, and 90% of 
these mutations are of the BRAF(V600E) (valine to glutamic acid substitution) [18, 19]. There is 
a well-established correlation between sun-exposure and the development of BRAF mutations 
[15, 20]. BRAF(V600E) mutation is observed in the benign melanocytic nevi, indicating that this 
mutation alone is not sufficient for malignant transformation [19, 21]. Other genetic changes 
such as CDKN2B loss are required for the progression from benign melanocytic nevus to mela-
noma [22]. Random mutagenesis screens have revealed that ERK point mutations impart resis-
tance to RAF and MEK inhibitors, although such mutations are infrequent [23].
4. Melanocyte origin and its intrinsic effects on melanoma metastasis
Melanoma is intrinsically prone to metastasis [4]. Melanocyte precursors are derived from 
highly migratory neural crest cells, which give rise to a number of differentiated cells includ-
ing the melanocytes. During this process, they express several canonical neural crest markers 
such as SOX8, SOX9, SOX10, Snail1, and Snail2. The strong metastatic potential of melanoma 
can be attributed to the plethora of mutations acquired over the development of the disease 
and to the aberrant reactivation of some of the transcriptional factors such as Sox5, Sox10, and 
Snail1 that are crucial for the melanocyte differentiation program [24–26].
The Wnt signaling pathway plays a major role in melanocyte differentiation and migration 
mainly through the activation of the microphthalmia-associated transcription factor (MITF) 
[27]. MITF promotes melanocyte differentiation and melanin production, in addition, MITF 
is often upregulated in melanomas associated with poor prognosis [28]. β-catenin dependent 
MITF activation induces proliferation of melanoma cells and inhibition of β-catenin leads to a 
cell cycle arrest along with downregulation of MITF [29]. Hyperactivated Wnt signaling has 
been reported in about 30% of melanoma samples [30] and is shown to promote melanoma-
genesis. On the other hand, there are also reports that demonstrate loss of β-catenin decreases 
melanoma cell proliferation, but promotes invasion and predicts poor prognosis [31]. This 
discrepancy is predominantly because the Wnt proteins utilize three distinct signaling path-
ways with different mediators [29]. The canonical Wnt signaling pathway entails activation 
of the frizzled surface receptors by the Wnt ligand, leading to the formation of a vast protein 
complex on the cell surface. This leads to a cascade of events, resulting in the nuclear trans-
location of β-catenin which then acts as a co-activator to regulate target gene expression [32]. 
A non-canonical Wnt signaling pathway involves activation of GTPases such as RAC1 and 
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RHOA, and MAP kinase such as JNK, downstream of the frizzled receptor. A second non-
canonical pathway includes activation of phospholipase C (PLC) that promotes the release 
of intracellular Ca2+, leading to the expression of target genes involved in cell migration and 
inflammation [33]. The noncanonical Wnt signaling is shown to stimulate cytoskeletal remod-
eling, increase cell survival, and promote invasive characteristics [34, 35]. Both the canonical 
and the noncanonical Wnt signaling pathways are involved in the promotion of melanoma 
cell proliferation and epithelial-mesenchymal translation (EMT) [29, 36].
5. Ubiquitination in melanoma
Posttranslational modification (PTM) is a reversible and dynamic process that regulates pro-
tein function at a posttranslational level and plays crucial roles in signal transduction, gene 
regulation, vesicle transportation, and protein degradation. PTMs include phosphorylation, 
ubiquitination, sumoylation, methylation, acetylation, glycosylation and N-nitrosylation. 
Dysregulation of PTM results in pathogenesis including cancer [37]. Phosphorylation is cata-
lyzed by protein kinases and is the core mediator of signal transduction. Oncogenic mutations 
of the protein kinases, most notably BRAF(V600E), result in constitutive phosphorylation and 
activation of the downstream targets such as the MEK and ERK kinases [38]. Kinase-mediated 
signals are also regulated by other PTMs including ubiquitination.
Ubiquitination (Ub) is a rather complex process involving a substantial series of variable com-
ponents. Mono-Ub involves a covalent attachment of a 76 amino acid ubiquitin polypeptide 
to a lysine residue of a target protein. Poly-Ub involves attachment of additional ubiquitin 
moieties to one of the seven lysine (K) residues (K6, K11, K27, K29, K33, K48 and K63) or the 
methionine residue (M1) of the proceeding ubiquitin, forming structurally and functionally 
distinct polymers. If more than one K-residues are involved, it is called a heteropolymeric 
chain and, if a single K-residue is involved, it is called as a homopolymeric chain, such as 
K48-Ub and K63-Ub [39]. Different Ubs carry out distinct functions, ensuring the robust 
control of essentially every cellular process spanning from signal transduction, DNA-repair, 
vesicle transportation, cell division, differentiation, and migration [40]. While K48-Ub gener-
ally marks protein for proteasomal degradation, K63-Ub regulates signal transduction, RNA 
splicing, protein sorting, DNA repair and immune response [41–43].
Ubiquitination generally requires a three-step process: the E1 enzyme catalyzes the first step by 
activating an ubiquitin moiety in the presence of ATP and the E2 conjugase carries the ubiquitin 
via covalent bonding, and works together with an E3 ligase to complete ubiquitin ligation with 
the target protein [44]. There are two known E1 enzymes, UBA1 and UBA6 [45]. The canonical 
UBA1 is characterized as a potential target for the treatment of hematologic malignancies [46]. 
The noncanonical UBA6 suppresses epithelial-mesenchymal transition of mammary epithelial 
cells [47]. The role of UBA1 and UBA6 in melanoma is not well-understood.
5.1. Ubiquitin conjugases in melanoma
There are about 50 known E2 conjugating enzymes. Each of them contains a conserved cyste-
ine residue that accepts the ubiquitin molecule activated by the E1 enzyme. A number of E2 
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enzymes have been implicated in melanoma. For example, Rad6 promotes melanoma devel-
opment and progression by inducing nuclear translocation of β-catenin [48]. Overexpression 
of E2-EPF UCP (ubiquitin carrier protein) promotes melanoma metastasis, while its down-
regulation decreases tumor invasion [49]. UBE2S targets VHL protein for proteasomal degra-
dation via a K48-Ub-mediated process. UBE2S is overexpressed in metastatic melanoma cell 
lines and mediates the degradation of VHL and a consequent upregulation of HIF-1α and 
VEGF proteins to promote distant metastasis and angiogenesis [50].
5.2. Ubiquitin ligases in melanoma
There are over 600 putative E3 Ubiquitin ligases in the human genome. These enzymes dis-
play substrate specificity, and have attracted tremendous attention for therapeutic targeting. 
The SCF ubiquitin ligases constitute the largest family of E3 ligase enzymes characterized 
by an F-box component that interacts with the substrate. Among the SCF family members, 
β-TrCP (beta transducing repeats containing protein) is upregulated in melanomas with 
BRAF(V600E) mutation and a corresponding increase of NF-κB activity [51]. Another SCF 
family member, SCF-Skp2 is shown to promote melanoma cell cycle progression by degrada-
tion of CDK inhibitors such as p27 and p57 [52]. FBXW7, a component of the SCF-FBW7 E3 
complex, is mutated in 8.1% of melanoma patients and some of these mutations interfere with 
its substrate binding, leading to oncogenic activation of substrates including Notch1 [53, 54]. 
FBXW7 inactivating mutations are detected in melanomas without the typical BRAF(V600E) 
and NRAS(G12D/G13R/Q61K/L/S) mutations [55]. Knockdown of FBXW7 in melanoma cell 
lines leads to the upregulation of NOTCH1, HEY1, and the downstream effectors Cyclin E, 
Aurora A and Myc, resulting in increased tumorigenesis [56–58].
The E3 ligase MDM2 regulates p53 and its expression in melanoma correlates with increased 
malignancy, tumor thickness and invasion [59]. TRAF6 is a K63-Ub ligase overexpressed in 
primary and metastatic melanoma, and it promotes tissue invasion by stimulating MMP9 
activation [60]. TRAF6 recruitment and activation is regulated by EGFR through the oncop-
rotein, DCBLD2 (discoidin, CUB, and LCCL domain-containing protein) in a number of can-
cers including melanoma [61]. TRAF6 together with p62 also regulates mTOR activation via 
K63-Ub which is important for the mTORC1 and mTORC2 complex formation [62]. TRAF2 
mediates K63-Ub of GβL (mTOR LST8 homolog) thereby preventing mTORC1 complex 
formation. Mutations in the K63-Ub site of GβL are shown to promote chemoresistance of 
melanoma cells in vitro and in the xenograft mouse model [63].
The E3 ubiquitin ligase RNF125 negatively regulates the retinoic acid-inducible gene I (RIG-
I) signaling pathway by targeting RIG-I for proteasomal degradation [64]. It also regulates 
p53 and innate immune adaptor protein TRIM14 [65, 66]. Deletion and missense mutations 
in RNF125 are linked to the overgrowth syndrome [67]. RNF125 is regulated by MITF and 
SOX10 transcription factors and its downregulation elevates JAK1 and EGFR signaling, and 
underlies resistance of melanoma cells to the BRAF inhibitor, vemurafenib [68].
Oncogenic RAS and BRAF mutants drive tumor growth through hyperactivation of ERK1/2 
kinases and concomitantly induce ERK-dependent negative feedback. Relief of this feedback 
inhibition by RAF inhibitors contributes to the attenuation of the therapeutic potency in BRAF 
mutant melanomas [69]. Ubiquitination-dependent degradation of BRAF constitutes for one of 
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the negative feedback mechanisms [70]. The APC/C E3 ligase complex activator FZR1 but not 
FBXW7 tumor suppressor controls BRAF oncogene function [70, 71]. FZR1 as a direct target of 
ERK and CyclinD1/CDK4 kinases and its phosphorylation inhibits APCFZR1, leading to increased 
expression of a cohort of oncogenic APCFZR1 substrates important for melanomagenesis [71].
The E3 ubiquitin ligase Trim7 is activated by the Ras/RAF/MEK/ERK pathway via MSK1-
mediated phosphorylation, and consequently mediates K63-Ub of the AP-1 co-activator 
RACO-1, leading to RACO-1 protein stabilization and increased AP-1-dependent gene expres-
sion [72]. The c-Jun/RHOB/AKT pathway confers resistance to BRAF mutant melanoma cells 
from BRAF and MEK inhibitors [73]. Trim7 may represent a potential target for combination 
therapies to mitigate therapeutic resistance.
5.3. Deubiquitinating enzymes in melanoma
Ubiquitination is a reversible process and a group of enzymes called the deubiquitinases (DUBs) 
cleave the isopeptide linkage between the polyubiquitin chains and the target proteins. There 
are five major families of deubiquitinases: ubiquitin-specific proteases (USP), ubiquitin car-
boxyl-terminal hydrolases (UCH), Jab1/MPN domain associated metalloisopeptidase domain 
proteins, Machado-Joseph Domain (Josephin domain) containing proteins (MJD) and Otubain/
Ovarian tumor domain containing proteins (OTU) [74]. Major functions of DUBs involve rescu-
ing incorrectly ubiquitinated proteins from degradation and modulating target protein function. 
DUBs play important roles in DNA repair, apoptosis, cell proliferation, kinase activation, and 
chromatin remodeling, and they can function as tumor suppressors as well as oncogenes [75].
5.3.1. Deubiquitinating enzymes acting as tumor suppressor
5.3.1 a BAP1 (BRCA-associated protein 1) is a deubiquitinase belonging to the ubiquitin 
C-terminal hydrolases family (UHCs). BAP1 binds to BRCA1, and acts a tumor suppressor. Loss 
of function of BAP1 due to germline mutations leads to the tumor predisposition syndrome 
which increases the risks of uveal and cutaneous melanomas, and malignant mesotheliomas. 
Individuals who carry the mutated BAP1 gene develop melanocytic lesions later in their life and 
some of those benign lesions can transform into cutaneous melanomas [76]. In addition to its 
deubiquitinase function, BAP1 possess a nuclear localization signal that allows it to translocate 
to the nucleus and interact with proteins such as HCF-1 to regulate cell growth [77].
5.3.1 b A20 (TNFAIP3) is a deubiquitinase commonly induced by inflammatory cytokines via 
NF-κB. It has an innate deubiquitinating activity imparted by the OUT zinc finger domain 
that allows it to interact with ubiquitinated substrates and maintain specificity. A20 inhibits 
auto-ubiquitination of the K63-Ub E3 ligase TRAF6, and consequently inhibits IKK/NF-κB 
activation [78]. Independent of its deubiquitinating functions, A20 disrupts the interaction 
between the E2 conjugase (UBE2N) and the E3 ligase (TRAF2/TRAF6), and consequently 
promotes K48-Ub and proteasomal degradation of these enzymes [79]. A20 is characterized 
as a potent tumor suppressor in non-Hodgkin’s lymphomas including diffuse large cell lym-
phoma, mantel cell lymphoma and ocular marginal zone B-cell lymphoma [80], but its role in 
melanoma is not at all clear. Increased expression of A20 in CD8+ T cells results in impaired 
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anti-tumor immunity in a melanoma animal model, while knockdown of A20 in CD8+ T cells 
increases cytokine production and decreases melanoma tumor burden [81].
5.3.1 c CYLD is a deubiquitinase that preferentially removes K63-Ub and M1-Ub from target 
proteins [82, 83]. CYLD has been identified as a tumor suppressor on account of its loss-of-func-
tion correlating to a number of cancers including melanoma [53, 84]. In addition to gene deletion 
and mutation, CYLD is downregulated by Snail1 at the transcriptional level and by microRNAs 
including mir-186 and mir-767 at the post-transcriptional level [85, 86]. Furthermore, CYLD 
is subject to proteolytic inactivation by MALT1, a paracaspase known to promote melanoma 
growth and metastasis through JNK/c-Jun signaling pathway [87]. CYLD exhibits anti-onco-
genic effects by regulating cell proliferation, angiogenesis, and tumor cell differentiation [88].
CYLD inhibits K63-Ub of a plethora of target proteins. Among these are Bcl3, TRAF2/6, Tak1, 
plk1, lck, HDAC6, Dvl, and c-Jun/c-Fos AP1 subunits [89–93]. In the absence of CYLD, Bcl3 
along with NF-κB is recruited to the Cyclin D1 promoter to facilitate its transcription to induce 
G1 to S cell cycle progression. CYLD inhibits JNK activation and expression of the β1-integrin 
in non-melanoma and melanoma cells with a corresponding decrease in cell proliferation and 
increase in apoptosis [88, 89]. On the other hand, CYLD regulates cell motility via inhibition of 
HDAC6-mediated deacetylation of tubulin and cortactin, by directly binding to the catalytic 
domain of HDAC6 [94, 95].
EMT and metastasis are orchestrated by an array of gene regulators, such as TWIST1/2, 
SNAIL1/2, ZEB1/2 and FOXC2 [96]. Snail1-mediated suppression of CYLD is crucial for mela-
noma progression and metastasis [97]. CYLD regulates EMT by facilitating the maintenance of 
E-Cadherin expression and inhibiting N-Cadherin expression in melanoma [84]. E-cadherin is 
a crucial protein facilitating cell-cell adhesion, maintaining cytoskeletal stability and regulat-
ing cell polarization. Germline mutations in E-cadherin predispose individuals to a higher 
risk of breast and gastric cancers [98]. E-cadherin appeared downregulated in melanoma 
predominantly due to the alterations in the tumor microenvironment rather than genetic 
mutations as reported in some gynecological cancers [99]. Loss of E-cadherin expression/
function increases melanocyte proliferation due to impaired interaction with keratinocytes 
[100]. When melanocytes are cultured in vitro, in the absence of the basal keratinocytes, they 
not only display increase in doubling time but also begin expression of melanoma-related 
markers such as β3-integrin, MUC18, melanotransferrin, and other growth factor receptors. 
These melanocytes regain their normal phenotype when co-cultured with keratinocytes [100]. 
E-cadherin also regulates the activation of β-catenin, c-Myc and Cyclin D1.
N-cadherin is expressed in melanoblasts during embryonic development, which helps cell 
migration from the neural crest to the epidermis by the way of interacting with fibroblasts and 
endothelial cells. In adults, upregulation of N-cadherin potentiates the ability of melanoma cells 
to invade through the stroma and interact with the vascular endothelial cells and fibroblasts, 
which facilitates migration of cancer cells. N-cadherin has also been demonstrated to stabilize 
β-catenin thereby promoting anti-apoptotic proteins and inhibiting pro-apoptotic proteins such 
as Bad [101]. Normal melanocytes do not express N-Cadherin, while melanoma cells display 
moderate to strong expression of N-cadherin with a corresponding decrease in the expression 
of E-cadherin. This phenomenon termed as the ‘cadherin switching’ is a hallmark of EMT [102].
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Snail1 also regulates the expression of Notch-4, MMP-2, TIMP-1, SPARC, and T-PA, among 
others, in melanoma cells [103]. Notch4 and SPARC expression can be directly regulated by 
Snail or indirectly via E-cadherin [103]. MMP-2 is a matrix metalloprotease that is involved 
in remodeling of the extracellular matrix through degradation of cell adhesion proteins and 
in turn facilitating tumor cell migration and invasion [104]. SPARC is a potent inducer of 
MMP-2, and downregulation of Snail1 decreases the expression of MMP-2 and SPARC [103, 
104], as well as T-PA, a protease that converts plasminogen to active zymogen [105], leading 
to reduced degradation of the extracellular matrix and subsequent invasion. Notch signaling 
mediates melanoma-endothelial cell and melanoma-keratinocyte communications, facilitat-
ing melanoma cell migration and metastasis [106, 107]. Notch 4 expression in melanoma 
is stimulated by Snail, independent of the repression of E-cadherin [103]. Notch inhibition 
enhances the efficacy of ERK and ERBB inhibitors for melanoma growth arrest [108, 109].
5.3.2. Deubiquitinating enzymes required for melanoma growth and metastasis
Deubiquitinases (DUB) have a role in stem cell maintenance and tumor growth [110]. Among 
the 89 DUBs examined in over 300 different tumor samples of breast, colon, lung, stomach, 
kidney, prostate, non-Hodgkin’s lymphoma, and melanoma, 22 DUBs are significantly dys-
regulated in at least one tumor type [111]. Specifically, three DUBs, USP10 (ubiquitin specific 
peptidase 10), USP11 and USP22, are expressed significantly higher in metastatic melanoma 
compared to benign nevi and primary tumor. In addition, expression of USP10 and USP22 
is significantly correlated to the presence of ulceration and the Breslow index, a prognostic 
parameter indicating the depth of tumor invasion. USP10, USP11 and USP22 regulate deu-
biquitination of target proteins crucial for melanoma transformation and metastasis [111]. 
For example, USP22 deubiquitinates chromosomal binding proteins H2A-Ub1 and H2A-Ub2, 
and consequently activates transcription factors and induces epigenetic modifications favor-
able for cancer growth and metastasis [112].
USP7 mediates degradation of tumor suppressors such as p53, MDM2, FOXO and PTEN 
[110]. USP14 is expressed at increased levels in melanoma cells compared to melanocytes, and 
its high expression correlates with melanoma progression and poorer survival. Knockdown 
or pharmacological inhibition of USP14 impairs viability of melanoma cells irrespective of 
the mutational status of BRAF, NRAS and TP53, and overcomes resistance to MAPK inhibi-
tors. This was accompanied by accumulation of poly-ubiquitinated proteins, mitochondrial 
dysfunction, ER stress, and a ROS production [113].
USP9X, another member of the USP family, is responsible for attenuating the degradation of 
Mcl-1, an anti-apoptotic protein in melanoma and other cancers [53]. USP9X deubiquitinates, 
and stabilizes ETS-1, a transcription factor involved in regulation of angiogenesis, cell migra-
tion, proliferation and cellular differentiation in melanoma [114]. Phenethyl ITC, an inhibitor 
of USP9X, is currently in a Phase I trial for the treatment of melanoma and leukemia and 
Phase II trials for oral and lung cancer [53]. WP1130 (degrasyn) is another agent that inhibits 
USP9X and promotes the accumulation of protein-ubiquitin conjugates, leading to formation 
of aggresomes and apoptosis. This agent is shown to decrease melanoma cell growth both 
in vitro and in vivo melanoma models [115].
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6. Conclusion
Melanoma is an aggressive disease intrinsically prone to metastasis. Germline and sporadic 
mutations are responsible for the initiation and progression of the disease and PTMs such as 
ubiquitination play dominant roles in melanoma growth and metastasis, and offer wealth of 
opportunities for therapeutic targeting. With better mechanistic understating of specific func-
tions of the ubiquitinating enzymes as well as the deubiquitinases, new targeted therapies are 
expected to emerge in the foreseeable feature.
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